Vacina COVID-19 em pacientes com urticária Posicionamento do Departamento Científico de Urticária da Associação Brasileira de Alergia e Imunologia (ASBAI) / COVID-19 vaccine in patients with urticaria Position statement of the Scientific Department of Urticaria of the Brazilian Association of Allergy and Immunology (ASBAI)
Arq. Asma, Alerg. Imunol
; 5(2): 115-119, abr.jun.2021. ilus
Article
in Pt
| LILACS
| ID: biblio-1398823
Responsible library:
BR2717.9
RESUMO
Com o início do programa de vacinação contra a COVID-19 no Brasil, surgiu uma série de questionamentos relacionados ao uso dos imunizantes em pacientes com doenças imunoalérgicas. Neste documento, o Departamento Científico de Urticária da Associação Brasileira de Alergia e Imunologia (ASBAI) se posiciona revisando as principais dúvidas relacionadas à imunização para COVID-19 em pacientes com urticária.
ABSTRACT
As the COVID-19 vaccination program started in Brazil, many questions have arisen regarding the use of vaccines in patients with immune-allergic diseases. In this document, the Scientific Department of Urticaria of the Brazilian Association of Allergy and Immunology takes a stand by reviewing the main queries regarding COVID-19 immunization in patients with urticaria.
Key words
Full text:
1
Index:
LILACS
Main subject:
Societies, Medical
/
Urticaria
/
Cyclosporine
/
Omalizumab
/
COVID-19 Vaccines
/
COVID-19
/
BNT162 Vaccine
/
2019-nCoV Vaccine mRNA-1273
/
ChAdOx1 nCoV-19
Type of study:
Guideline
/
Risk_factors_studies
Limits:
Humans
Country/Region as subject:
America do sul
/
Brasil
Language:
Pt
Journal:
Arq. Asma, Alerg. Imunol
Journal subject:
Biologia
/
Cincia
Year:
2021
Type:
Article